{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:52:02Z","timestamp":1787611922383,"version":"build-2736575974"},"reference-count":91,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FOREUM research grant","award":["2020-2024"],"award-info":[{"award-number":["2020-2024"]}]},{"name":"National Psoriasis Foundaton","award":["2020-2023"],"award-info":[{"award-number":["2020-2023"]}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["IJMS"],"abstract":"<jats:p>Biological drugs have revolutionized the treatment of many chronic diseases, starting with cancer. They normally consist of antibodies that are also effectively used to treat several autoimmune diseases, including psoriasis. These products, called biologics, work by selectively blocking the activity of certain targets, mainly cytokines, which play a crucial role in the pathogenic and inflammatory processes involved in a particular disease. Unfortunately, a reduction in response to these biological treatments may occur over time, and this phenomenon is often due to the development of antibodies against the therapeutic antibodies. The immune responses directed to these therapeutics range from transient anti-drug antibodies (ADA) formation, with no clinical significance, to the generation of high titers and persistence of ADA, causing loss of efficacy. Considering the costs associated with the use of biological drugs, there is growing interest in identifying biomarkers that can predict clinical response to personalize treatments.<\/jats:p>","DOI":"10.3390\/ijms26199616","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T09:38:08Z","timestamp":1759397888000},"page":"9616","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Phenomenon of Anti-Drug Antibodies in Psoriasis: Mechanisms, Clinical Impact, and Therapeutic Strategies"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0975-793X","authenticated-orcid":false,"given":"Anna","family":"Mennella","sequence":"first","affiliation":[{"name":"National Center for Global Health, Istituto Superiore di Sanit\u00e0, ISS, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6924-3826","authenticated-orcid":false,"given":"Loredana","family":"Frasca","sequence":"additional","affiliation":[{"name":"National Center for Global Health, Istituto Superiore di Sanit\u00e0, ISS, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1398-9995.2009.02280.x","article-title":"Anti-infliximab IgE and non-IgE Antibodies and Induction of Infusion-related Severe Anaphylactic Reactions","volume":"65","author":"Vultaggio","year":"2010","journal-title":"Allergy"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41584-020-00540-8","article-title":"Immunogenicity of Biologic Agents in Rheumatology","volume":"17","author":"Strand","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of Anti-TNF Biologic Therapies for Rheumatoid Arthritis","volume":"9","author":"Rispens","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000478077","article-title":"The Immunogenicity of Biologic Therapies","volume":"Volume 53","author":"Puig","year":"2018","journal-title":"Current Problems in Dermatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1136\/annrheumdis-2017-eular.4861","article-title":"SAT0141 Optimal Circulating Adalimumab Levels Range Associated with Good Clinical Response in Rheumatoid Arthritis Patients","volume":"76","author":"Jochems","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-Term Follow-Up","volume":"305","author":"Bartelds","year":"2011","journal-title":"J. Am. Med. Assoc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaci.2016.09.014","article-title":"Neutralizing Capacity of Monoclonal and Polyclonal Anti-Natalizumab Antibodies: The Immune Response to Antibody Therapeutics Preferentially Targets the Antigen-Binding Site","volume":"139","author":"Kruithof","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/jid.2012.390","article-title":"CD8+ T Cells Mediate RAS-Induced Psoriasis-Like Skin Inflammation through IFN-\u03b3","volume":"133","author":"Gunderson","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s12026-020-09149-1","article-title":"The Role of Th17 Cells in Psoriasis","volume":"68","author":"Li","year":"2020","journal-title":"Immunol. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1084\/jem.20090480","article-title":"Self-RNA\u2013Antimicrobial Peptide Complexes Activate Human Dendritic Cells through TLR7 and TLR8","volume":"206","author":"Ganguly","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in Plaque Psoriasis\u2014Results of Two Phase 3 Trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The Immunogenicity of Humanized and Fully Human Antibodies: Residual Immunogenicity Resides in the CDR Regions","volume":"2","author":"Harding","year":"2010","journal-title":"mAbs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and Therapy of Psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/511051","article-title":"A Large-Scale Genetic Association Study Confirms IL12B and Leads to the Identification of IL23R as Psoriasis-Risk Genes","volume":"80","author":"Cargill","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/330662a0","article-title":"Anti-Cachectin\/TNF Monoclonal Antibodies Prevent Septic Shock during Lethal Bacteraemia","volume":"330","author":"Tracey","year":"1987","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2249.1993.tb03457.x","article-title":"Localization of Tumour Necrosis Factor-Alpha (TNF-\u03b1) and Its Receptors in Normal and Psoriatic Skin: Epidermal Cells Express the 55-kD but Not the 75-kD TNF Receptor","volume":"94","author":"Kristensen","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaci.2010.12.009","article-title":"Human Slan (6-Sulfo LacNAc) Dendritic Cells Are Inflammatory Dermal Dendritic Cells in Psoriasis and Drive Strong T 17\/T 1 T-Cell Responses","volume":"127","author":"Ingwersen","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1172\/JCI27180","article-title":"Activated Macrophages Are Essential in a Murine Model for T Cell-Mediated Chronic Psoriasiform Skin Inflammation","volume":"116","author":"Wang","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1523-1747.1999.00749.x","article-title":"The Majority of Epidermal T Cells in Psoriasis Vulgaris Lesions Can Produce Type 1 Cytokines, Interferon-\u03b3, Interleukin-2, and Tumor Necrosis Factor-\u03b1, Defining TC1 (Cytotoxic T Lymphocyte) and TH1 Effector Populations:1 a Type 1 Differentiation Bias Is Also Measured in Circulating Blood T Cells in Psoriatic Patients","volume":"113","author":"Austin","year":"1999","journal-title":"J. Investig. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Toussirot, \u00c3., Aubin, F., and Dumoulin, G. (2014). Relationships between Adipose Tissue and Psoriasis, with or without Arthritis. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00368"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s13555-021-00520-0","article-title":"Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results","volume":"11","author":"Umezawa","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00403-021-02273-4","article-title":"Attitudes and Behaviour Regarding Dose Reduction of Biologics for Psoriasis: A Survey among Dermatologists Worldwide","volume":"314","year":"2022","journal-title":"Arch. Dermatol. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1080\/09546634.2022.2043546","article-title":"Serum Drug Levels and Anti-Drug Antibodies in the Context of Dose Tapering by Interval Prolongation of Adalimumab, Etanercept and Ustekinumab in Psoriasis Patients: Results of the CONDOR Trial","volume":"33","author":"Atalay","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","article-title":"Individualized Monitoring of Drug Bioavailability and Immunogenicity in Rheumatoid Arthritis Patients Treated with the Tumor Necrosis Factor \u03b1 Inhibitor Infliximab","volume":"54","author":"Bendtzen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/annrheumdis-2015-208849","article-title":"High Frequency of Antidrug Antibodies and Association of Random Drug Levels with Efficacy in Certolizumab Pegol-Treated Patients with Rheumatoid Arthritis: Results from the BRAGGSS Cohort","volume":"76","author":"Jani","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Arstikyte, I., Kapleryte, G., Butrimiene, I., and Venalis, A. (2015). Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF \u03b1 Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients. BioMed Res. Int., 2015.","DOI":"10.1155\/2015\/604872"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1093\/rheumatology\/kead177","article-title":"The Role of Antidrug Antibodies in Ustekinumab Therapy and the Impact of Methotrexate","volume":"62","author":"Henke","year":"2023","journal-title":"Rheumatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/BOR.0b013e328329ed8b","article-title":"Dealing with Immunogenicity of Biologicals: Assessment and Clinical Relevance","volume":"21","author":"Wolbink","year":"2009","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1586\/1744666X.2013.836060","article-title":"Anti-Drug Antibodies in Psoriasis: A Critical Evaluation of Clinical Significance and Impact on Treatment Response","volume":"9","author":"Hsu","year":"2013","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/bjd.14965","article-title":"Secukinumab, a Fully Human Anti-Interleukin-17A Monoclonal Antibody, Exhibits Minimal Immunogenicity in Patients with Moderate-to-Severe Plaque Psoriasis","volume":"176","author":"Reich","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/bjd.15706","article-title":"Secukinumab Sustains Good Efficacy and Favourable Safety in Moderate-to-Severe Psoriasis after up to 3 Years of Treatment: Results from a Double-Blind Extension Study","volume":"177","author":"Bissonnette","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jaad.2019.05.094","article-title":"Immunogenicity and Skin Clearance Recapture in Clinical Studies of Brodalumab","volume":"82","author":"Bagel","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.jid.2018.04.019","article-title":"Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis","volume":"138","author":"Reich","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/jdv.18042","article-title":"Anti-drug Antibodies of IL-23 Inhibitors for Psoriasis: A Systematic Review","volume":"36","author":"Norden","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/bjd.17918","article-title":"Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Efficacy and Safety of Tildrakizumab","volume":"182","author":"Kimball","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Anjie, S.I., Gecse, K.B., Meloni, C.M., Vidal-Itriago, A., L\u00f6wenberg, M., and D\u2019Haens, G.R. (Clin. Gastroenterol. Hepatol., 2025). Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs. Combination Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis, Clin. Gastroenterol. Hepatol., in press.","DOI":"10.1016\/j.cgh.2025.03.021"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e3015","DOI":"10.6061\/clinics\/2021\/e3015","article-title":"Immunogenicity to Biological Drugs in Psoriasis and Psoriatic Arthritis","volume":"76","author":"Valenzuela","year":"2021","journal-title":"Clinics"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Hu, R., Yuan, T., Wang, H., Zhao, J., Shi, L., Li, Q., Zhu, C., Su, N., and Zhang, S. (2023). Efficacy, Safety and Immunogenicity of Etanercept Biosimilars versus Reference Biologics in Patients with Rheumatoid Arthritis: A Meta-Analysis. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1089272"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jid.2020.03.957","article-title":"Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study","volume":"140","author":"Loeff","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/19420862.2015.1136761","article-title":"Secukinumab, a Novel Anti\u2013IL-17A Antibody, Shows Low Immunogenicity Potential in Human in Vitro Assays Comparable to Other Marketed Biotherapeutics with Low Clinical Immunogenicity","volume":"8","author":"Karle","year":"2016","journal-title":"mAbs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s13555-016-0121-x","article-title":"Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials","volume":"6","author":"Farahnik","year":"2016","journal-title":"Dermatol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jid.2019.02.018","article-title":"Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis","volume":"139","author":"Zhu","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Atiqi, S., Hooijberg, F., Loeff, F.C., Rispens, T., and Wolbink, G.J. (2020). Immunogenicity of TNF-Inhibitors. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00312"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/FTD.0000000000000404","article-title":"Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context","volume":"39","author":"Bloem","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal Antibody Pharmacokinetics and Pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s40262-015-0361-4","article-title":"Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics","volume":"55","author":"Gill","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40262-015-0296-9","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis","volume":"54","author":"Ternant","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"eaat3356","DOI":"10.1126\/scitranslmed.aat3356","article-title":"Dynamics of Circulating TNF during Adalimumab Treatment Using a Drug-Tolerant TNF Assay","volume":"11","author":"Berkhout","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/s41591-019-0568-2","article-title":"A Single T Cell Epitope Drives the Neutralizing Anti-Drug Antibody Response to Natalizumab in Multiple Sclerosis Patients","volume":"25","author":"Cassotta","year":"2019","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40259-023-00641-2","article-title":"Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies","volume":"38","author":"Harris","year":"2024","journal-title":"BioDrugs"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/archdermatol.2009.347","article-title":"Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis","volume":"146","author":"Lecluse","year":"2010","journal-title":"Arch. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1346-8138.2010.00882.x","article-title":"Anti-infliximab Antibody Status and Its Relation to Clinical Response in Psoriatic Patients: A Pilot Study","volume":"37","author":"Aral","year":"2010","journal-title":"J. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bjd.19690","article-title":"The Value of Subcutaneous vs. Oral Methotrexate: Real-world Data from the German Psoriasis Registry PsoBest","volume":"184","author":"Reich","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00403-019-01945-6","article-title":"Effectiveness of Methotrexate in Moderate to Severe Psoriasis Patients: Real-World Registry Data from the Swiss Dermatology Network for Targeted Therapies (SDNTT)","volume":"311","author":"Drach","year":"2019","journal-title":"Arch. Dermatol. Res."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Vultaggio, A., Perlato, M., Nencini, F., Vivarelli, E., Maggi, E., and Matucci, A. (2021). How to Prevent and Mitigate Hypersensitivity Reactions to Biologicals Induced by Anti-Drug Antibodies?. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.765747"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1001\/archdermatol.2008.502","article-title":"Is Leflunomide Effective in the Treatment of Psoriasis in a Patient Who Is Unable to Benefit From Standard First- and Second-Line Therapies and Needs an Affordable Treatment Option?","volume":"144","author":"Affleck","year":"2008","journal-title":"Arch. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Vaisman-Mentesh, A., Gutierrez-Gonzalez, M., DeKosky, B.J., and Wine, Y. (2020). The Molecular Mechanisms That Underlie the Immune Biology of Anti-Drug Antibody Formation Following Treatment With Monoclonal Antibodies. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01951"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1158\/1078-0432.CCR-21-0168","article-title":"Antidrug Antibodies and Drug Development: Challenges in the Immunotherapy Era","volume":"27","author":"Moreno","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.tibtech.2018.05.008","article-title":"Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins","volume":"36","author":"Sauna","year":"2018","journal-title":"Trends Biotechnol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jaad.2009.05.042","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Phase I Study of MEDI-545, an Anti\u2013Interferon-Alfa Monoclonal Antibody, in Subjects with Chronic Psoriasis","volume":"62","author":"Bissonnette","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"639","DOI":"10.4161\/mabs.2.6.13583","article-title":"ATROSAB, a Humanized Antagonistic Anti-Tumor Necrosis Factor Receptor One-Specific Antibody","volume":"2","author":"Zettlitz","year":"2010","journal-title":"mAbs"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.04.068","article-title":"The Infliximab Biosimilar in the Treatment of Moderate to Severe Plaque Psoriasis","volume":"75","author":"Dapavo","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/ard.2006.055111","article-title":"Selective Costimulation Modulation Using Abatacept in Patients with Active Rheumatoid Arthritis While Receiving Etanercept: A Randomised Clinical Trial","volume":"66","author":"Weinblatt","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/art.38896","article-title":"Combined Inhibition of Tumor Necrosis Factor \u03b1 and Interleukin-17 As a Therapeutic Opportunity in Rheumatoid Arthritis: Development and Characterization of a Novel Bispecific Antibody","volume":"67","author":"Fischer","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1021\/acs.molpharmaceut.5b00268","article-title":"Development of a Trispecific Antibody Designed to Simultaneously and Efficiently Target Three Different Antigens on Tumor Cells","volume":"12","author":"Dimasi","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12016-018-8668-1","article-title":"Psoriasis: From Pathogenesis to Targeted Therapies","volume":"54","author":"Conrad","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Moots, R.J., Xavier, R.M., Mok, C.C., Rahman, M.U., Tsai, W.-C., Al-Maini, M.H., Pavelka, K., Mahgoub, E., Kotak, S., and Korth-Bradley, J. (2017). The Impact of Anti-Drug Antibodies on Drug Concentrations and Clinical Outcomes in Rheumatoid Arthritis Patients Treated with Adalimumab, Etanercept, or Infliximab: Results from a Multinational, Real-World Clinical Practice, Non-Interventional Study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0175207"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jim.2007.07.004","article-title":"An Affinity Capture Elution (ACE) Assay for Detection of Anti-Drug Antibody to Monoclonal Antibody Therapeutics in the Presence of High Levels of Drug","volume":"327","author":"Bourdage","year":"2007","journal-title":"J. Immunol. Methods"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.clim.2009.05.007","article-title":"Immunogenicity of Rituximab in Patients with Severe Pemphigus","volume":"132","author":"Schmidt","year":"2009","journal-title":"Clin. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jim.2015.01.007","article-title":"Systematic Comparison of Drug-Tolerant Assays for Anti-Drug Antibodies in a Cohort of Adalimumab-Treated Rheumatoid Arthritis Patients","volume":"418","author":"Bloem","year":"2015","journal-title":"J. Immunol. Methods"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1007\/s11095-012-0833-2","article-title":"A Survey of Applications of Biological Products for Drug Interference of Immunogenicity Assays","volume":"29","author":"Wang","year":"2012","journal-title":"Pharm. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jim.2005.10.007","article-title":"Detection of Neutralizing Anti-Therapeutic Protein Antibodies in Serum or Plasma Samples Containing High Levels of the Therapeutic Protein","volume":"308","author":"Lofgren","year":"2006","journal-title":"J. Immunol. Methods"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","article-title":"Antidrug Antibodies (ADAb) to Tumour Necrosis Factor (TNF)-Specific Neutralising Agents in Chronic Inflammatory Diseases: A Real Issue, a Clinical Perspective","volume":"72","author":"Vincent","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_75","first-page":"e78954","article-title":"Intra-Class Interleukin-(IL)-17 Blocker Switching: Ixekizumab as a Solution for Secukinumab Non-Responders in Secondary Biologic Failure in Psoriasis","volume":"17","author":"De","year":"2025","journal-title":"Cureus"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2521082","DOI":"10.1080\/09546634.2025.2521082","article-title":"Switching Biologic Agent in Patients with Psoriasis: A Systematic Review and Meta-Analysis","volume":"36","author":"Zhang","year":"2025","journal-title":"J. Dermatol. Treat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jdin.2023.05.006","article-title":"Real-World Effectiveness and Safety of Risankizumab in Patients with Plaque Psoriasis in Whom Guselkumab Failed Recently: A Multicenter Retrospective Study of Switching within the Interleukin-23 Inhibitor Class","volume":"12","author":"Bagit","year":"2023","journal-title":"JAAD Int."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaad.2018.01.003","article-title":"Efficacy and Safety of Switching to Ixekizumab in Secukinumab Nonresponders with Plaque Psoriasis: A Multicenter Retrospective Study of Interleukin 17A Antagonist Therapies","volume":"79","author":"Georgakopoulos","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jaad.2013.10.019","article-title":"Efficacy of Switching between Tumor Necrosis Factor-Alfa Inhibitors in Psoriasis: Results from the Italian Psocare Registry","volume":"70","author":"Piaserico","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/dth.12267","article-title":"An Evolution in Switching Therapy for Psoriasis Patients Who Fail to Meet Treatment Goals","volume":"28","author":"Kerdel","year":"2015","journal-title":"Dermatol. Ther."},{"key":"ref_81","first-page":"e15760","article-title":"Guselkumab as a Switching Strategy after anti-TNF\u03b1, anti-IL17, or anti-IL12\/23 Therapies in Moderate-to-severe Psoriasis","volume":"35","author":"Chinchay","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/bjd.12764","article-title":"Switching Biological Agents for Psoriasis in Secondary Care: A Single-Centre, Retrospective, Open-Label Study","volume":"170","author":"Woo","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/ard.2005.043158","article-title":"Baseline Comorbidity Levels in Biologic and Standard DMARD Treated Patients with Rheumatoid Arthritis: Results from a National Patient Register","volume":"65","author":"Hyrich","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/qjmed\/hcq152","article-title":"TNF- Antagonists beyond Approved Indications: Stories of Success and Prospects for the Future","volume":"103","author":"Karampetsou","year":"2010","journal-title":"QJM Int. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/ar3395","article-title":"Are We Ready for Therapeutic Drug Monitoring of Biologic Therapeutics?","volume":"13","author":"Krieckaert","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Krishna, M., and Nadler, S.G. (2016). Immunogenicity to Biotherapeutics\u2014The Role of Anti-Drug Immune Complexes. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00021"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3897\/folmed.66.e114887","article-title":"Prognostic Models of Drug-Induced Neutralizing Antibody Formation in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis Treated with TNF-\u03b1 Blockersockers","volume":"66","author":"Kraev","year":"2024","journal-title":"Folia Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2333729","DOI":"10.1080\/19420862.2024.2333729","article-title":"In Silico Methods for Immunogenicity Risk Assessment and Human Homology Screening for Therapeutic Antibodies","volume":"16","author":"Mattei","year":"2024","journal-title":"mAbs"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2324836","DOI":"10.1080\/19420862.2024.2324836","article-title":"T and B Cell Epitope Analysis for the Immunogenicity Evaluation and Mitigation of Antibody-Based Therapeutics","volume":"16","author":"Sun","year":"2024","journal-title":"mAbs"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13075-024-03277-x","article-title":"Prediction of Ineffectiveness of Biological Drugs Using Machine Learning and Explainable AI Methods: Data from the Austrian Biological Registry BioReg","volume":"26","author":"Ukalovic","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1759720X211014010","article-title":"Biomarkers Predictive of Treatment Response in Psoriasis and Psoriatic Arthritis: A Systematic Review","volume":"13","author":"Magee","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9616\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T09:38:21Z","timestamp":1759397901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":91,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ijms26199616"],"URL":"https:\/\/doi.org\/10.3390\/ijms26199616","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]}}}